

Clinical Decision Options[®]

Gastrointestinal



bioconcepts
innovative nutritional solutions

Introducing Bio Concepts Clinical Decision Options (CDO)®

What is a CDO?

The Bio Concepts Clinical Decision Options (CDO) is a new tool created to support your clinical choices and deliver superior information for therapeutic considerations, strategies and outcomes.

What does the CDO offer as a clinical tool?

Bio Concepts has developed CDOs to assist you in your critical decision-making process, as an adjunct to your own clinical experience and expertise, in the formulation of effective treatment plans for your patients. This Gastrointestinal CDO is designed to help identify symptoms, determine appropriate testing, interpret results and guide your clinical considerations with researched ingredients to deliver the best possible clinical outcomes. The Bio Concepts Gastrointestinal CDO also includes clinical outlines for gut repair, function and maintenance and wherever you see these icons **1** **2** **3** refer to pages 12 and 13 of this booklet. **Important note:** Throughout this booklet we have highlighted the 'red flag' medical referral moments with this icon **!**

Table of Contents

Common GIT Disorder Presentations	3
Adverse Food Reactions	4-7
Immune Mediated	4-5
Autoimmune Food Reactions	4
Coeliac Disease	4
Food Allergies	4-5
Peptic Ulceration & GORD (differential diagnosis)	4-5
Food Sensitivities	5
Non-Immune Mediated	6-7
Non-Toxic Food Reactions	6
Food Intolerances	6
Toxic Food Reactions	7
IBS (differential diagnosis)	7
GIT Infection	8-11
Pathology testing	8-11
Stool analysis	8
Microbial overgrowth	8
Candida albicans	8-9
Intestinal permeability	9
Urea breath test	9
Helicobacter pylori	9
Hydrogen & methane breath test	9
Small Intestinal Bacterial Overgrowth	9
Muscle Fibres, Vegetable Fibres & Fat Stain	10
Butyrate, SCFAs, Secretory IgA	10
Lactoferrin, Calprotectin, lysozyme, White Blood Cells & Mucous	10
Inflammatory Bowel Disease	11
Ulcerative Colitis	11
Crohn's Disease	11
Gut Repair, Function & Maintenance	12-13
Researched Nutrient & Dosage Chart	14-17
References	18-19
Related Resources	19

Common GIT Disorder Presentations

There are many gastrointestinal symptoms and disorders that patients may experience. Among the most common are adverse food reactions and GIT infection.

Presentation 1

Adverse Food Reactions

Refer to page 4-7

Symptoms associated with adverse food reactions:

- Abdominal pain
- Bloating
- Constipation & diarrhoea
- Nausea
- Hypersensitivity
- Breathing difficulties & asthma
- Headaches & migraine
- Fluid retention
- Skin rashes, acne, eczema & psoriasis
- Anxiety & depression
- Dizziness, fatigue & lethargy
- Pre-existing conditions:
 - Gastric ulcers
 - Irritable Bowel Syndrome (IBS)
 - Coeliac Disease
 - Crohn's Disease (CD)
 - Arthritis
 - Autism
 - Epilepsy
 - Fibromyalgia
 - Multiple Sclerosis
 - Chronic Fatigue Syndrome

Presentation 2

GIT Infection

Refer to page 8-11

Symptoms associated with GIT infection:

- Nausea
- Vomiting
- Fever
- Loss of appetite
- Fatigue
- Muscle aches
- Dehydration
- Headache
- Mucous or blood in the stool
- Bloating
- Abdominal pain
- Diarrhoea
- Constipation
- Belching
- Flatulence
- Weight loss

Presentation 3

Refer to page 4-11

Symptoms associated with adverse food reactions & GIT infection:

- Any combination of the above listed symptoms.

The CDO tool is not for use in a medical emergency. Refer immediately for acute abdominal pain emergencies which include: "worst ever ripping or tearing" to describe pain; fever; occult blood or blood in the urine; pregnancy; uncontrolled vomiting; lightheadedness on standing; acute onset of pain; intensifying pain over time; trauma to abdomen; abdominal pain with walking; distended abdomen; excessive abnormal sweating with pain; pain which awakens from sleep or a pulsatile abdominal mass.

Adverse Food Reactions

Presentation 1 or 3

Immune Mediated

Autoimmune Food Reactions

T-cell mediated eg. Coeliac Disease

Investigations:

- Diet & symptom diary (See *Bio Concepts Diet & Symptom Diary*)
 - **Refer:** to the GP for Coeliac serology testing and diagnostic investigations
 - Autoantibodies: tTG-IgA, EMA-IgA, DGP-IgG (indicative, not diagnostic)
 - Gene testing: HLA-DQ2 & HLA-DQ8 (shows genetic predisposition, not diagnostic)
 - Small intestinal endoscopy & biopsy (diagnostic)
 - A Complete Digestive Stool Analysis (CDSA) may reveal more information about inflammatory markers and digestion which may be useful
- Refer to GIT Infection Chart (pages 7-10)**

Important note: Dietary intake of gluten is required for accurate testing results. If a patient is undergoing testing, do not remove gluten from the diet until investigations are complete; 21% of Coeliac patients have no symptoms; 27% present with diarrhoea, weight loss & malabsorption; other common presentations include constipation, anaemia, osteoporosis, neurological disorders or dermatitis herpetiformis.

Symptom management: Patients who have Coeliac Disease or gluten sensitivity may experience symptoms such as nausea, vomiting, abdominal pain and diarrhoea during the testing process due to increased gluten intake advised during this time. Support with herbal digestive teas (fennel, peppermint, ginger, chamomile), digestive enzymes, adequate hydration & supplementation to manage the potential increase in nutrient loss.



Mechanisms behind autoimmune conditions include chronic inflammation driven by abnormal cytokine biology & higher than normal levels of autoreactive CD4+ T-cells



Investigate:

Consider other food reactions
Refer to Adverse Food Reactions Chart (pages 4-7)
 If dysbiosis or GIT infection is suspected
Refer to GIT Infection Chart (pages 8-11)
 Consider a differential diagnosis.

1 2 3

Clinical Considerations:

Phase 1-3: Gut Repair, Function & Maintenance

Main goals: Reduce inflammation & repair the gut lining, support the microbiota & optimal immune function & address nutritional deficiencies commonly associated with Coeliac Disease if present (protein, Vitamins A & D, Iron, B12, Folate, Zinc & Magnesium).

Diet: Strict lifelong avoidance of gluten-containing foods, consider cross-reactive foods, diverse whole food diet, no alcohol, consider a Mediterranean Diet (high in Omega-3).

Lifestyle: Avoid cooking items such as toasters & chopping boards that come in contact with gluten-containing foods, be cautious when eating out, gluten-free products are not always highly nutritious – keep the diet as diverse as possible to support the core microbiota & prevent nutritional deficiencies. Minimise stress which often exacerbates Coeliac disease & avoid environmental triggers (autoimmune disease can move in and out of remission based on health and lifestyle factors).

Food Allergies

IgE mediated reactions usually occur immediately or within a few hours of consumption



Refer: Patients experiencing breathing difficulty, swelling of the tongue or any symptoms suggesting anaphylaxis require urgent assessment by a specialist physician.

Investigations:

- Antigen specific serum IgE testing
- Diet & symptom diary may assist to identify the likely food trigger. Common food allergies include milk, eggs, nuts, soy, sesame, fish & shellfish.
- Elimination diet & food challenge may be required if the patient is reacting to multiple foods.
- Assess all supplement ingredients used during this time (if any permitted) for possible triggers. (See *Bio Concepts Elimination Diet handout*).



Clinical Considerations:

Phase 1-3: Gut Repair, Function & Maintenance

Main goals: Reduce symptoms, strict avoidance of reactive foods generally for life (sensitisation programs may be offered as an option through a specialist immunologist), support immune function & stabilise mast cells, support digestion, reduce inflammation & repair the gut lining & prolonged gut healing may improve food tolerance.

Diet: Strict avoidance of reactive foods, diverse, whole food diet, a long-term restricted diet is not recommended, diversifying the diet as much as possible to include high quality prebiotic foods may help to enhance the core microbiota and, in turn, support a healthy immune response.



Investigate:

Consider other food reactions
Refer to Adverse Food Reactions Chart (pages 4-7)
 If dysbiosis or GIT infection is suspected
Refer to GIT Infection Chart (pages 8-11)
 Consider other IgE reaction causes such as topical or inhaled triggers. Consider a differential diagnosis.

Peptic Ulceration and GORD

Investigations:

- Hydrogen breath test (*H.pylori*)
- Barium oesophagram
- Endoscopy & biopsy

Clinical Considerations:

Phase 1-3: Gut Repair, Function & Maintenance

Main goals: Reduce symptoms, reduce BMI, insulin resistance, reduce stress & detrimental lifestyle factors, address hypochlorhydria and support digestion. Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) both as a causal and maintaining factor.

Refer: Patients should consult their prescribing physician for assessment of their medications eg. Proton-pump inhibitors (PPIs), nitroglycerine, anticholinergics & benzodiazepenes may impact digestive health.

Diet: Avoid trigger foods eg. chocolate, coffee, alcohol (also affects sphincter function), chilli & fatty meals; protein sufficiency is important to ensure healthy collagen production 0.8-1.2g/kg, encourage a diverse, whole food diet adapted for weight loss if required; eat slowly & small meals more regularly. Avoid peppermint oil which is commonly used for indigestion but may negatively affect sphincter function.

Food Sensitivities

IgG, IgA & IgM mediated reactions usually occur hours to days after consumption

Investigations:

- Antigen specific serum IgG/IgG4 & IgA testing
- Serum LPS & zonulin testing (non-specific intestinal barrier function tests)
- Lactulose/mannitol testing (indicative of intestinal permeability from all causes)
- Diet & symptom diary (See *Bio Concepts Diet & Symptom Diary*)
- Elimination diet (See *Bio Concepts Elimination Diet handout*)



Likely aetiology: intestinal permeability

Clinical Considerations:

Phase 1-3: Gut Repair, Function & Maintenance

Main goals: Reduce symptoms, remove reactive foods/food groups, promote gut repair, reduce inflammation, stabilise mast cells & prevent histamine release, support immune function & microbiota diversity. Withhold fermentable fibre until inflammation &/or dysbiotic overgrowth have resolved to avoid symptom exacerbation. Support digestion & nutrient assimilation.

Diet (Phase 1-3): Diverse, whole food diet, strictly avoid reactive foods & include therapeutic gut healing foods such as bone broths. Replace & balance the nutrients lacking due to eliminated foods. Consider additional dietary modifications if required. FODMAPs diet short-term only as restricted diets may compromise long-term outcomes for the microbiota.

Investigate:

Consider other food reactions
Refer to Adverse Food Reactions Chart (pages 4-7)
 If dysbiosis or GIT infection is suspected
Refer to GIT Infection Chart (pages 8-11)
 Consider a differential diagnosis.

Clinical Considerations:

Phase 2: Gut Repair & Function

Main goals: Continue reducing inflammation, soothe the GIT mucous membrane. Introduce fermentable fibres to help restore microbiota balance & diversity & improve bowel function/motility. Reduce pathogenic load. If present **refer to GIT Infection Chart (pages 8-11)**. Address the gut-brain axis & relieve anxiety (if present) & support detoxification.

Clinical Considerations:



Phase 3: Gut Repair & Maintenance

Main goals: Continue active maintenance of the GIT integrity, epithelial barrier function & gap junctions. Reduce pathogenic load. If present **refer to GIT Infection Chart (pages 8-11)**. Promote the growth of beneficial bacteria & microbiota diversity. Continue to reduce inflammation. Educate patients on how to avoid exacerbations by considering dietary & lifestyle choices eg. alcohol consumption. Prevent infection if travelling overseas.

Continue Phase 3 Repair & Maintenance until symptoms subside and then consider re-introducing eliminated foods one-by-one into the diet from least reactive to most reactive, while staying on the Phase 3 supportive nutrients. If an adverse reaction occurs, consider eliminating this food for a longer period, continue Phase 3 Repair & Maintenance and attempt reintroduction again later in the healing process. Encourage an ongoing diverse diet, including Fructooligosaccharide (FOS) & Galactooligosaccharide (GOS)-containing foods to enhance the foundations of the core microbiota & diversify native populations.

Adverse Food Reactions


Presentation 1 or 3



GIT Infection

Presentation 2 or 3


Pathology-driven differential diagnosis of GIT infection



GIT Infection


Presentation 2 or 3

Pathology-driven differential diagnosis of GIT infection



Repair Function Maintenance

1



Phase 1: Repair

Week 1 - 4

1. Remove reactive foods/food groups
2. Promote gut repair by improving GIT integrity & epithelial barrier & gap junction function: Glutamine, Turmeric, Quercetin, Zinc carnosine, Vitamins A & D
3. Reduce inflammation: Turmeric, Quercetin, Glutamine, Vitamins A & D, Zinc carnosine, Omega-3 fatty acids
4. Support immune function, stabilise mast cells & prevent histamine release: Quercetin, Zinc, Vitamins A & D
5. Reduce pathogenic load & support microbiome diversity: Quercetin, Turmeric (Quercetin & Turmeric act as non-fermentable prebiotics), Glutamine, Vitamins A & D & multi-strain probiotics
6. Withhold fermentable fibre until inflammation & dysbiotic overgrowth have resolved
7. Support digestion & nutrient assimilation: hydrochloric acid & digestive enzymes

Assess symptoms at weeks 2 & 4*



1. Continue Phase 1 Gut Repair for another 2-4 weeks & then reassess (Phase 1 Gut Repair may require 12 or more weeks depending on the severity of the case & compliance)
2. Consider further investigations (other immune or non-immune mediated reactions, CDSA to assess microbiology & key markers of digestion, absorption & inflammation – **Refer to infection Chart (pages 7-10)**)
3. Consider cross-reactive foods
4. Address lifestyle factors such as stress & exercise that impact greatly on gut health
5. Other contributing factors such as alcohol consumption & medications: eg. NSAIDs, antibiotics & PPIs

2



Phase 2: Repair & Function

Week 5 - 8

1. Introduce fermentable fibre: FOS, Psyllium, Slippery elm
2. Continue reducing inflammation: Turmeric, FOS, Licorice, Omega-3 fatty acids
3. Soothe the GIT mucous membranes: Slippery elm, Marshmallow, Licorice
4. Reduce pathogenic load: FOS, Marshmallow, Licorice, Psyllium
5. Restore microbiome balance & diversity: FOS, Marshmallow, Licorice, Psyllium, Slippery elm, Turmeric
6. Improve bowel function & motility: FOS, Psyllium, Lemon balm
7. Address the gut-brain axis & relieve anxiety: Psyllium, FOS, Lemon balm, Turmeric
8. Support detoxification: Turmeric, Licorice, Psyllium, B vitamins, Antioxidants, Sulphur-containing amino acids

Assess symptoms at weeks 6 & 8*



1. Continue Phase 2 Gut Repair & Function for another 2-4 weeks & then reassess (Phase 2 Gut Repair may require 12 or more weeks depending on the severity of the case & compliance)
2. Consider further investigations - other immune or non-immune mediated reactions, CDSA to assess microbiology & key markers of digestion, absorption & inflammation – **Refer to infection Chart (pages 7-10)**
3. Consider cross-reactive foods
4. Address lifestyle factors such as stress & exercise that impact greatly on gut health
5. Other contributing factors such as alcohol consumption & medications: eg. NSAIDs, antibiotics & PPIs
6. Refer for a second opinion if required

3



Phase 3: Repair & Maintenance

Week 9 - 12

1. Continue reducing inflammation: Zinc carnosine, *S.boulevardii*, Omega-3 fatty acids
2. Maintain gap junctions, GIT integrity & epithelial barrier function: Zinc Carnosine
3. Reduce pathogenic load: *S. boulevardii*
4. Promote the growth of beneficial bacteria: *S. boulevardii*
5. Promote microbiome diversity: *S. boulevardii*
6. Prevent infection if travelling overseas: *S. boulevardii*
7. Improve *H.pylori* eradication rates: Zinc carnosine, *S. boulevardii*
8. Reduce negative effects associated with food reactions: Zinc carnosine, *S. boulevardii*

Assess symptoms at week 12*



1. Continue Phase 3 Gut Repair & Function for another 2-4 weeks and then reassess (Phase 3 Gut Repair may require 12 or more weeks depending on the severity of the case & compliance)
2. Consider further investigations - other immune or non-immune mediated reactions, CDSA to assess microbiology & key markers of digestion, absorption & inflammation – **Refer to infection Chart (pages 7-10)**
3. Consider cross-reactive foods
4. Address lifestyle factors such as stress & exercise that impact greatly on gut health
5. Other contributing factors such as alcohol consumption & medications: eg. NSAIDs, antibiotics & PPIs
6. Refer for a second opinion if required

Maintenance

Week 12+

1. Continue Phase 3 Repair & Maintenance until symptoms subside & then consider reintroducing eliminated foods (if possible) one-by-one into the diet from least reactive to most reactive, while staying on the Phase 3 supportive nutrients
 - If an adverse reaction occurs, consider eliminating this food for a longer period, continue Phase 3 Repair & Maintenance & attempt reintroduction again later in the healing process
2. Encourage an ongoing diverse, whole food diet including FOS & GOS-containing foods to enhance the foundations of the core microbiome & build native populations
3. Address lifestyle factors such as stress & exercise that impact greatly on gut health

*Each patient will have individual features that affect their time to recovery & may require more or less time to optimise gut healing. Let the patient's symptoms & feedback guide you through this process timeframe.

Refer to the Nutrient & Dosage Chart page 14-17 for the recommended dosages and treatment duration as outlined in research.

Marked improvement

Little or no improvement

Researched Nutrient & Dosage Chart

Nutrient/ Herb	Clinically Researched Dose	Rationale/Research	Action
B. longum BB536	112 - 427 million CFU daily	<ul style="list-style-type: none"> <i>Bacteroides fragilis</i> - decreased pathogen at week 8 in treatment group, with no effects on controls.¹ 	Antimicrobial
Betaine hydrochloride; Glutamic acid; Pepsin		<ul style="list-style-type: none"> Supplemental HCl (available as Betaine HCl and often combined with Glutamic Acid), has been shown to significantly reduce stomach pH in induced hypochlorhydria.² Pepsin is the predominant proteolytic enzyme in the stomach. It facilitates the breakdown of protein in the diet, and requires HCl for its activation. To function optimally, pepsin requires a pH between 1.8 and 3.5.³ Its activity decreases when the pH reaches 5 or above.^{4,3,5} In hypochlorhydric states, activation of endogenous pepsinogen into pepsin is stalled, consequently impairing protein digestion. However, as pepsinogen is activated by HCl or a combination of HCl and preformed pepsin, supplementation is able to correct this imbalance.³ 	Improve hydrochloric acid production and digestive capacity
Digestive enzymes: protease, bromelains, trypsin		<ul style="list-style-type: none"> Trypsin is part of a family of protease enzymes that fragment proteins. Unlike pancreatic enzymes, bromelain has a relatively broad pH range through which it can remain effective, providing proteolytic activity in the stomach as well as in the intestine.⁶ Bromelain may therefore offer additional support for protein digestion when combined with pancreatin. 	Digestive support
Fructooligosac- charides FOS (Crohn's Disease)	2g+ daily	<ul style="list-style-type: none"> Increases <i>Bifidobacterium</i> spp., <i>Lactobacillus</i> spp., and <i>Faecalibacterium prausnitzii</i>. Increases SCFAs.⁷ Reduces TNFα, IL-6, IL-8, IL-1β. Increases IL-10 producing dendritic cells. Reduces faecal calprotectin.⁷ 	Microbiome balance; anti- inflammatory
FOS	2.5g+ daily	<ul style="list-style-type: none"> Restores microbiome diversity - nourishes <i>Faecalibacterium</i> and <i>Bifidobacterium</i> populations. Promotes butyrate production. Increases beneficial bacteria and reduces non-beneficial bacteria.⁸ Improves bowel motility - selectively stimulates the growth of <i>Bifidobacteria</i>, improves stool consistency and bowel function.^{9,8} Anti-inflammatory - improves gut barrier function, increases beneficial bacteria & reduces non-beneficial bacteria.⁸ Anxiety - increased faecal bifidobacterial concentrations with a subsequent improvement in anxiety.⁹ 	Microbiome balance; bowel function; anti- inflammatory; anxiolytic
Glutamine	10-15g for 8 weeks	<ul style="list-style-type: none"> Major energy source for epithelial cells Role in mucosal integrity Depleted by infection Clinical trial: 5g Glutamine TDS for 8 weeks restored intestinal permeability in post infectious IBS patients.¹⁰ Improves epithelial integrity, downregulates NF-kB, preserves gut barrier function, maintains tight gap junctions, and provides fuel for enterocytes.¹⁰ 	Protects gap junctions, gut healing, antimicrobial, improves microbiota
Glycyrrhiza glabra (Licorice)		<ul style="list-style-type: none"> Restores microbiome diversity - stimulates <i>Lactobacilli</i> and <i>Bifidobacterium</i> spp. Increases butyrate which reduces non-beneficial bacteria and favours mucin production.¹¹ Soothes the GIT - soothes mucous membranes. Provides demulcent and anti-ulcerogenic actions.^{12,13,14} Reduces inflammation - provides antimicrobial, anti-ulcerogenic, anti-spasmodic and anti-inflammatory actions. Supports detoxification, providing antimicrobial, antioxidant and hepatoprotective actions.^{12,13} 	Microbiome balance; demulcent; anti- inflammatory; antimicrobial; anti-ulcerogenic; hepatoprotective
Althea officinalis (Marshmallow)		<ul style="list-style-type: none"> Restores microbiome diversity - promotes healthy bowel flora. Provides anti-inflammatory and antimicrobial actions.¹⁵⁻¹⁷ Soothes the GIT - relieves inflamed mucous membranes. Provides vulnerary and demulcent actions.^{11,16,17} 	Microbiome balance; demulcent; vulnerary

Nutrient/ Herb	Clinically Researched Dose	Rationale/Research	Action
Melissa officina- lis (Lemon balm)		<ul style="list-style-type: none"> Regulates bowel motility - provides carminative and antispasmodic actions.^{18,19,20} Relieves anxiety - improves functional gastrointestinal complaints associated with anxiety. Anxiolytic actions.^{18,19} 	Carminative; antispasmodic; anxiolytic; antibacterial to <i>E.coli</i>
N-acetylcyste- ine		<ul style="list-style-type: none"> Impairs <i>Staphylococcus aureus</i> biofilm formation without inducing cytotoxic effects²¹; NAC has good antibacterial properties and interferes with biofilm formation.²² 	Antimicrobial; detoxification support
N-acetylcyste- ine (H.pylori)	400mg three times daily + Clarithromycin & Lansoprazole	<ul style="list-style-type: none"> NAC had an additive effect on eradication rates of <i>H.pylori</i> with medications; NAC may have improved the delivery of antibiotics to the infection site by reducing mucous thickness.²³ 	Antimicrobial
Omega-3 fatty acids (IBD & H.pylori)		<ul style="list-style-type: none"> Reduce inflammation in IBD²⁴ Omega-3 PUFAs could reduce various <i>H. pylori</i>-associated gastric diseases, including gastric cancer by influencing multiple targets, including proliferation, survival, angiogenesis, inflammation, and metastasis.²⁵ 	Anti- inflammatory; prebiotic
Omega-3 fatty acids (IBS, Functional GIT disorders, Coeliac Disease)		<ul style="list-style-type: none"> Omega-3 PUFAs exert significant effects on the intestinal environment; on mood and cognitive functioning, such as anxiety and depression; and modulating the gut microbiota composition.²⁶ Omega-3 PUFAs can be considered prebiotics. 	Prebiotic
Probiotics (IBD)		<ul style="list-style-type: none"> Increase SCFAs, mucous secretion, IL-10; decrease TNFα, NF-kB, IL-1β, IL-β, TLR expression; enhance epithelial barrier function.⁷ 	Anti- inflammatory; improve gut barrier function
Psyllium		<ul style="list-style-type: none"> Restores microbiome diversity - increases butyrate production. Shapes a desirable microbiome by correcting disturbed bowel flora.²⁷ Improves bowel motility - softens the stool, reduces discomfort and straining.^{27,28} Relieves anxiety - improves bowel symptoms, microbiome diversity and quality of life parameters, including anxiety, physical discomfort and straining.²⁸ Supports detoxification - binds bile acids which causes increased bile acid excretion. Provides mucilage & polysaccharides and normalises stool consistency and transit time.^{27,29} 	Microbiome balance; bowel function & motility; detoxification support; anxiolytic
Quercetin	500mg daily	<ul style="list-style-type: none"> Inhibits histamine release³⁰ Protects tight junction barrier function by regulating tight junction proteins and inflammatory signalling pathways.³¹ Gut microbial composition can be modulated by polyphenols.³² Quercetin has been demonstrated to prevent intestinal permeability in response to toxic agents, the rise in the levels of proinflammatory cytokines and pathologically provoked intestinal motility.³³ NSAID-induced mitochondrial dysfunction³³ Meta-analysis: Showed a significant reduction in circulating CRP at doses of 500mg daily.³⁴ Clinical trial: Study of rheumatoid arthritis patients found 500mg of Quercetin reduced pain, stiffness and inflammatory markers including TNFα.³⁵ Quercetin produced by microbial transformation demonstrated antimicrobial activity against <i>S. aureus</i> by effectively inhibiting the growth and dispersion of preformed biofilms³⁶; induces apoptosis by modulating quorum sensing.³³ 	Anti- inflammatory; antimicrobial; improves microbiota; non-fermentable prebiotic; protects gap junctions; gut healing

Researched Nutrient & Dosage Chart

Nutrient/ Herb	Clinically Researched Dose	Rationale/Research	Action
Saccharomyces boulardii	5-10billion CFU daily	<ul style="list-style-type: none"> <i>Blastocystis hominis</i> - 77.7% of treatment group achieved a clinical cure at day 15; after one month clinical cure rate was 94.4%.³⁷ <i>Candida albicans</i> - as effective as nystatin (anti-fungal) at reducing fungal infection, progressive fungal colonisation & incidences of clinical sepsis.³⁸ <i>Clostridium difficile</i> - stool analysis showed those with lower <i>S. boulardii</i> after treatment had higher clostridium recurrence.³⁹ <i>Giardia lamblia</i> - in combination with antibiotic therapy, led to reduced pathogen numbers.⁴⁰ <i>H. pylori</i> - in children the eradication rate was 93.3% in treatment group with 30% reduction in side effects⁴¹; in adults it reduced side effects of triple therapy.⁴² 	Antimicrobial; microbiome balance
Ulmus rubra (Slippery elm)		<ul style="list-style-type: none"> Restores microbiome diversity - provides polysaccharides and mucilage. Increases butyrate-producing bacteria.¹¹ Soothes the GIT - provides mucilage to protect the mucosal barrier function in the GIT.^{11,43} 	Microbiome balance; demulcent; vulnerary; laxative
Thyme, Clove and Oregano oils, with the herbs Black walnut, Wormwood, Pau d'arco, Barberry and Garlic		See Bio Concepts' <i>Gastrointestinal Diverse Clinical Applications Chart</i>	Antimicrobial
Curcuma longa (Turmeric)		<ul style="list-style-type: none"> Restores microbiome diversity - provides polyphenols for positive effects on gastrointestinal microbiota modulation and neuroendocrine system health (gut-brain axis).^{32,44} Reduces inflammation - reduces multiple markers of gastrointestinal inflammation such as NF-κB and TNF-α. Improves gut barrier function. Increases Intestinal Alkaline Phosphatase (IAP) and helps reduce the impact of endotoxins.^{45,46,47} Supports detoxification - supports detoxification by promoting bile flow and glucuronidation. Provides hepatoprotective and antioxidant actions.^{45,48,49,50,51} Strengthens intestinal barrier function - improves intestinal barrier function and reduces bacterial translocation.⁵² Antimicrobial - influences the function of immune cells involved in IBD, inhibits TLR4 and NF-κB and AP-1 signal transduction.⁵² 	Microbiome diversity; anti- inflammatory; supports detoxification; anti-microbial; non-fermentable prebiotic
Vitamin A		<ul style="list-style-type: none"> Promotes epithelial cell proliferation and healing and increases mucous production from goblet cells. Required for the development of immune tolerance in the intestine.⁵³ Increases the abundance of <i>Lactobacillus</i> spp. in the gut Regulates the expression of tight junction genes in epithelial cells and restores tight junctions.⁵⁴ Strengthens the barrier function of epithelial cells in the absence of probiotic bacteria. 	Promotes healthy cell turnover; vulnerary; microbiota balance; regulates gene expression; repairs gap junctions
Vitamin C		<ul style="list-style-type: none"> The inhibitory effect of Vitamin C on biofilm formation proceeds by inhibition of quorum sensing and other stationary phase regulatory mechanisms underpinning biofilm development which specifically leads to inhibition of polysaccharide biosynthesis.⁵⁵ 	Biofilm inhibiting

Nutrient/ Herb	Clinically Researched Dose	Rationale/Research	Action
Vitamin D	1000IU-2000IU for 12 weeks	<ul style="list-style-type: none"> Role in maintaining the integrity of the intestinal barrier. Enhances the tight junctions that control mucosal permeability. Deficiency leads to disruption of the gut barrier and dysbiosis; and low <i>Akkermansia muciphila</i> which is associated with ulcerative colitis.⁵⁶ D3 supplementation diminishes the competitive advantage of opportunistic pathogens.⁵⁶ Clinical trial: Patients with ulcerative colitis were given 1000IU-2000IU daily for 12 weeks. Both doses improved patients' quality of life and level of disease activity reduced in the 2000IU group only.⁵⁷ 	Anti- inflammatory; improves microbiota; protects gap junctions; gut healing
Vitamin D (IBD)		<ul style="list-style-type: none"> Exerts protective mechanisms through modulation of gut commensal bacteria, reducing inflammation and immunomodulatory actions⁵⁸ (reduces Th1, Th17, dendritic cell maturation, enhances epithelium barrier function and autophagy, increases IL-10, and reduces IFN-γ, IL-17, IL-12).⁵⁸ 	Anti- inflammatory; microbiome balance; improves gut barrier function
Zinc carnosine (ZnC)	75mg- 150mg daily for 4 weeks	<ul style="list-style-type: none"> ZnC dissociates slowly in gastric secretions. This prolonged existence in the stomach maintains the healing effect for a longer time.⁵⁹ Approved as an anti-ulcer drug; adheres to and penetrates ulcers which then undergo wound healing.⁵⁹ Clinical trial: ZnC at 37.5mg BD given alongside standard doses of NSAIDs demonstrated no significant increase in intestinal permeability.⁶⁰ Clinical trial: Patients taking daily low-dose aspirin were given 150mg ZnC for 4 weeks and showed a significant reduction in the median number of reddened lesions and erosions/ulcers on follow up capsule endoscopy.⁶¹ Clinical trial: Patients taking 74mg BD ZnC alongside triple therapy for <i>H. pylori</i> demonstrated significantly higher eradication (77.0%) compared to triple therapy alone (48.6%) with no serious adverse events.⁶² 	Protects gap junctions; anti-ulcerogenic; gut healing

References

- Odamaki T, Sugahara H, Yonezawa S, et al. Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides fragilis in microbiota. Anaerobe. 2012;18(1):14-18. doi:10.1016/j.anaerobe.2011.11.004
- Knapp MJ, Berardi RR, Dressman JB, Rider JM, Carver PL. Modification of gastric pH with oral glutamic acid hydrochloride. Clin Pharm. 1991;10(11):866-869. http://europepmc.org/abstract/med/1686581.
- Guyton AC, Hall JE. Textbook of Medical Physiology. London: W S Saunders; 1996.
- Gropper SS, Smith J. Advanced Nutrition and Human Metabolism. 6th ed. Wadsworth/Thompson; 2013.
- Schlenker ED, Long S. William's Essential of Nutrition and Diet Therapy. Elsevier; 2007.
- Roxas M. The role of enzyme supplementation in digestive disorders. Altern Med Rev. 2008;13(4):307-314.
- Healey GR, Else S, Jacobson K, Sly M, Vallance BA. Inflammatory bowel disease and immunonutrition : novel therapeutic approaches through modulation of diet and the gut microbiome. doi:10.1111/imm.12939
- Tandon D, Haque MM, Gote M, et al. A prospective randomized, double-blind, placebo-controlled, dose-response relationship study to investigate efficacy of fructo-oligosaccharides (FOS) on human gut microflora. Sci Rep. 2019;9(1):1-15. doi:10.1038/s41598-019-41837-3
- Azpiroz F, Dubray C, Bernalier-Donadille A, et al. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double blind, placebo controlled study. Neurogastroenterol Motil. 2017;29(2):1-8. doi:10.1111/nmo.12911
- Zhou Q, Verne M, Fields J, et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996-1002.
- Peterson CT, Sharma V, Uchitel S, et al. Prebiotic Potential of Herbal Medicines Used in Digestive Health and Disease. J Altern Complement Med. 2018;24(7):656-665. doi:10.1089/acm.2017.0422
- Al-snafi A. Glycyrrhiza glabra : A phytochemical and pharmacological review. IOSR J Pharm www.iosrphr.org. 2018;8(6):1-17.
- Committee S. Glycyrrhiza glabra. In: British Herbal Pharmacopoeia. West Yorks: British Herbal Medicine Association; 1983.
- Harwansh R, Patra K, Pareta S, Singh J, Biswas R. PHARMACOLOGICAL STUDIES ON GLYCYRRHIZA GLABRA: A REVIEW. Pharmacologyonline. 2011;(June).
- Committee S. Althaea officinalis. In: British Herbal Pharmacopoeia. West Yorks: British Herbal Medicine Association; 1983.
- Thomsen M. Althaea officinalis. In: Phytotherapy Desk Reference. 2nd ed. Global Natural Medicine; 2001.
- Council AB. Althaea officinalis. Expanded Commission E.
- American Botanical Council. Lemon balm. Expanded Commission E Monographs. http://cms.herbalgram.org/expandedE/LemonBalm.html. Published 2000.
- Committee S. Melissa officinalis. In: British Herbal Pharmacopoeia. West Yorks: British Herbal Medicine Association; 1983.
- Shakeri A, Sahebkar A, Javadi B. Melissa officinalis L. - A review of its traditional uses, phytochemistry and pharmacology. J Ethnopharmacol. 2016;188:204-228. doi:10.1016/j.jep.2016.05.010
- Costa F, Sousa DM, Parreira P, Lamghari M, Gomes P, Martins MCL. N-acetylcysteine-functionalized coating avoids bacterial adhesion and biofilm formation. 2017;(May):1-13. doi:10.1038/s41598-017-17310-4
- Blasi F, Page C, Maria G, et al. The effect of N -acetylcysteine on biofilms : Implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190-197. doi:10.1016/j.rmed.2016.06.015
- Gurbuz AK, Ozel AM, Ozturk R, Yildirim S, Yazgan Y, Demirturk L. Effect of N-acetyl cysteine on Helicobacter pylori. South Med J. 2005;98(11):1095-1098.
- Maria S, Alvares R De, Quesada K, Dib M. Inflammatory bowel disease : can omega-3 fatty acids really help ? 2016:37-43.
- Park J-M, Jeong M, Kim E-H, Han Y-M, Kwon SH, Hahm K-B. Omega-3 Polyunsaturated Fatty Acids Intake to Regulate Helicobacter pylori -Associated Gastric Diseases as Nonantimicrobial Dietary Approach . Biomed Res Int. 2015;2015:1-11. doi:10.1155/2015/712363
- Costantini L, Molinari R, Farinon B, Merendino N. Impact of omega-3 fatty acids on the gut microbiota. Int J Mol Sci. 2017;18(12). doi:10.3390/ijms18122645
- Jalanka J, Major G, Murray K, et al. The effect of psyllium husk on intestinal microbiota in constipated patients and healthy controls. Int J Mol Sci. 2019;20(2):1-12. doi:10.3390/ijms20020433
- Erdogan A, Rao SSC, Thiruvaiyaru D, et al. Randomised clinical trial : mixed soluble / insoluble fibre vs . psyllium for chronic constipation. Aliment Pharmacol Ther. 2016;44(1):35-44. doi:10.1111/apt.13647
- Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017;8(2):172-184. doi:10.1080/19490976.2017.1290756
- Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut. 2016;65(1):155-168. doi:10.1136/gutjnl-2015-309151
- Lee B, Moon KM, Kim CY. Tight Junction in the Intestinal Epithelium: Its Association with Diseases and Regulation by Phytochemicals. J Immunol Res. 2018;2018(Figure 2):1-11. doi:10.1155/2018/2645465
- Filosa S, Di Meo F, Crispi S. Polyphenols-gut microbiota interplay and brain neuromodulation. Neural Regen Res. 2018;13(12):2055-2059. doi:10.4103/1673-5374.241429
- Singh, Devendra Pratap, Swapnil P. Borse and MN. Overcoming the Exacerbating effects of ranitine on NSAID-induced small intestinal toxicity with quercetin: Providing a complete GI solution. J Chem Interact. 2017;272:53-64.
- Mohammadi-Sartang M, Mazloom Z, Sherfatmanesh S, Ghorbani M, Firoozi D. Effects of supplementation with quercetin on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2017;71(9):1033-1039. doi:10.1038/ejcn.2017.55
- Javadi F, Ahmadzadeh A, Egtesadi S, et al. The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial. J Am Coll Nutr. 2017;36(1):9-15. doi:10.1080/07315724.2016.1140093
- Sarangapani S, Jayachitra A. Targeting biofilm inhibition using Quercetin – Interaction with bacterial cell membrane and ROS mediated biofilm control. Funct Foods Heal Dis. 2018;8(6):292. doi:10.31989/ffhd.v8i6.510
- Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res. 2011;108(3):541-545. doi:10.1007/s00436-010-2095-4
- Demirel G, Celik IH, Erdevi O, Saygan S, Dilmen U, Canpolat FE. Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. Eur J Pediatr. 2013;172(10):1321-1326. doi:10.1007/s00431-013-2041-4
- Elmer GW, McFarland L V, Surawicz CM, Dankos L, Greenbergs RN. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther. 1999;13(12):1663-1668. doi:10.1046/j.1365-2036.1999.00666.x
- Besirbellioglu BA, Ulcay A, Can M, et al. Saccharomyces boulardii and infection due to Giardia lamblia. Scand J Infect Dis. 2006;38(6-7):479-481. http://www.tandfonline.com/doi/abs/10.1080/00365540600561769. Accessed March 31, 2016.
- Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr. 2009;98(1):127-131. doi:10.1111/j.1651-2227.2008.00977.x
- Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97(11):2744-2749. doi:10.1111/j.1572-0241.2002.07063.x
- Committee S. Ulmus rubra. In: British Herbal Pharmacopoeia. West Yorks: British Herbal Medicine Association.
- Ozdal T, Sela DA, Xiao J, Boyacioglu D, Chen F, Capanoglu E. The reciprocal interactions between polyphenols and gut microbiota and effects on bioaccessibility. Nutrients. 2016;8(2):1-36. doi:10.3390/nu8020078
- Prucksunand C, Indrasukhsri B, Leethochawalit M, Hungspreugs K. Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer. Pub Med Commons. Southeast Asian J Trop Med Public Heal. 2001;32(1):208-215.
- Soleimani V, Sahebkar A, Hosseinzadeh H. Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review. Phytres. 2018;32(6):985-995. doi:10.1002/ptr.6054
- Mantzorou M, Pavlidou E, Vasios G, Tsalgalioti E, Giaginis C. Effects of curcumin consumption on human chronic diseases : A narrative review of the most recent

- clinical data. Phytres. 2018;32(6):957-975. doi:10.1002/ptr.6037
- Kunnumakkara AB, Bordoloi D, Padmavathi G, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325-1348. doi:10.1111/bph.13621
- Council A botanical. Curcuma longa. Expanded Commission E. http://cms.herbalgram.org/expandedE/Turmericroot.html. Published 2019.
- Farzaei MH, Zobeiri M, Parvizi F, et al. Curcumin in liver diseases: A systematic review of the cellular mechanisms of oxidative stress and clinical perspective. Nutrients. 2018;10(7). doi:10.3390/nu10070855
- Salehi B, Stojanovi Z, Mateji J, Shari M, Shari J, Kumar NVA. The therapeutic potential of curcumin : A review of clinical trials. Eur J Med Chem. 2019;163:527-545. doi:10.1016/j.ejmech.2018.12.016
- Burge K, Gunasekaran A, Chaaban H. Curcumin and Intestinal Inflammatory Diseases : Molecular Mechanisms of Protection. 2019.
- Louder DT, Khandelwal P, Dandoy CE, et al. Lower levels of Vitamin A are associated with increased gastrointestinal graft-versus-host disease in children. Blood. 2017;129(20):2801-2807. doi:10.1182/blood-2017-02-765826
- Abdelhamid L, Luo XM. Retinoic acid, leaky gut, and autoimmune diseases. Nutrients. 2018;10(8). doi:10.3390/nu10081016
- Pandit S, Ravikumar V, Abdel-Haleem AM, et al. Low concentrations of vitamin C reduce the synthesis of extracellular polymers and destabilize bacterial biofilms. Front Microbiol. 2017;8(DEC):1-11. doi:10.3389/fmicb.2017.02599
- Bakke D, Sun J. Ancient Nuclear Receptor VDR with New Functions: Microbiome and Inflammation. Inflamm Bowel Dis. 2018;24(6):1149-1154. doi:10.1093/ibd/izy092
- Karimi S, Tabataba-Vakili S, Yari Z, et al. The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status. Nutr J. 2019;18(1):1-8. doi:10.1186/s12937-019-0441-7
- Hassanshahi M, Anderson PH, Sylvester CL, Stringer AM. Minireview Highlight article Current evidence for vitamin D in intestinal function and disease. 2019;25:1040-1052. doi:10.1177/1535370219867262
- Matsukura T, Tanaka H. Applicability of Zinc Complex of L-Carnosine for Medical Use. Biochemistry. 2000;65(7):817-823.
- Mahmood A, FitzGerald AJ, Marchbank T, et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007;56(2):168. doi:10.1136/GUT.2006.099929
- Watari I, Oka S, Tanaka S, Aoyama T, Imagawa H, Shishido T. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy : a pilot randomized controlled study. BMC Gastroenterol. 2013;13(1):1. doi:10.1186/1471-230X-13-108
- Tan B, Luo H-Q, Xu H, et al. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. 2017. doi:10.1371/journal.pone.0175625

Related Resources




Elimination Diet Handout



Diet and Symptom Diary Notepad




Food and Lifestyle Diary Notepad



Gastrointestinal Diverse Clinical Applications Chart

Visit bioconcepts.com.au to download your copy

Copyright © 2019 Bio Concepts.



Technical Support: 1800 077 113
visit www.bioconcepts.com.au



bioconcepts
innovative nutritional solutions



orthoplex
white



orthoplex
green



orthoplex
blue

*Please note Orthoplex White products can only be purchased if you are a Orthoplex White approved customer.
Always read the label. Use only as directed. If symptoms persist consult your healthcare practitioner.*